You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Ireland

Apr 2011

Price: US$2,400

About this Report

About this Report

Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Ireland with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Ireland, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Ireland for free:

The Consumer Health in Ireland market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Ireland?
  • What are the major brands in Ireland?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Consumer health continues to see growth

Consumer health products continue to perform well in Ireland with positive growth for 2010, despite the continuing economic crisis and reduced levels of consumer spending. Value for money is a key driving factor, due in part to economic conditions. However, an increasing awareness of health and wellness issues and a growing willingness to self-medicate have also aided growth.

Display of codeine-based analgesics – new guidance now in force

As of 1 August 2010, new guidelines for the display and sale of codeine-based analgesics came into effect. Pharmacists must follow strict guidelines from the PSI (Pharmacy Society of Ireland) on sales and the suitability of over the counter pain relief products, with products containing paracetamol now being the preferred first line of treatment, followed by ibuprofen, before codeine products should be used. Customers must now also be made aware of how to use the medication properly and the possible effects from use after the recommended period or overdose.

Customers seeking value for money

As Ireland remains firmly in the grip of recession, consumer choices remain clearly focused on prevention rather than cure, so that staying healthy and keeping well is of key importance. With job security an issue for many people and performance reviews being closely monitored by employers, taking time off sick is just not an option they wish to consider. However, while they wish to remain well, they are also seeking value for money. Multi-functional products are growing in popularity compared to single-benefit products across a wide range of categories aimed at various segments and demographics.

Health & Beauty Retailers Continue to Dominate

A large proportion of consumer health products in Ireland are pharmacy-only products, however many of the 15,000 Irish pharmacies also provide an extensive range of other OTC consumer health products, presented by well-trained staff capable of offering professional advice and opinion on products, ensuring that Health and Beauty Retailers continue to enjoy the majority of coverage for the Consumer Health market in Ireland in value terms. In the face of this difference in availability of products and the professionalism and level of care offered in these outlets, other channels continue to struggle to gain market share.

Growth – slow but steady

Slow but steady growth is expected for the forecast period, with continued expansion in sales, but at a slower rate compared to the review period. If the government moves forward with its plans to allow the generic substitution of prescription medication, the Irish public will become more used to generic products, possibly causing a ripple effect on OTC sales. Sales performance may be improved if more products are de-listed as the government attempts to reduce costs to the General Medical Services (GMS) budget.

Table of Contents

Table of Contents

Consumer Health in Ireland - Industry Overview

EXECUTIVE SUMMARY

Consumer health continues to see growth

Display of codeine-based analgesics – new guidance now in force

Customers seeking value for money

Health & Beauty Retailers Continue to Dominate

Growth – slow but steady

KEY TRENDS AND DEVELOPMENTS

Irish economy struggles to recover from recession

Obesity reaches crisis levels

Pharmacy changes – current and future issues

Prevention is better than cure

Rapid response versus immune defence

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Consumer Health Company Shares by Value 2006-2010
  • Table 6 Consumer Health Brand Shares by Value 2007-2010
  • Table 7 Penetration of Private Label by Category 2005-2010
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC registration and classification

De-listing and de-reimbursement

Advertising

Packaging and labelling

Distribution

Vitamins and dietary supplements registration and classification

EU Legislation

Self-medication/self-care and preventative medicine

Generics

Switches

  • Summary 1 Consumer Health : Switches 2009-2010

DEFINITIONS

Sources

  • Summary 2 Research Sources

Consumer Health in Ireland - Company Profiles

Beeline Healthcare Ltd in Consumer Health (Ireland)

STRATEGIC DIRECTION

  • Summary 3 Beeline Healthcare Ltd: Key Facts

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 4 Beeline Healthcare Ltd: Competitive Position 2010

Pharma Nord ApS in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 6 Pharma Nord ApS : Competitive Position 2010

Pinewood Healthcare Group in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 8 Pinewood Healthcare Group: Production Statistics 2010

COMPETITIVE POSITIONING

  • Summary 9 Pinewood Healthcare Group: Competitive Position 2010

Seven Seas Ireland Ltd in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 11 Seven Seas Ireland Ltd: Competitive Position 2010

Sona Nutrition Ltd in Consumer Health (Ireland)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 13 Sona Nutrition Ltd Production Statistics 2010

COMPETITIVE POSITIONING

  • Summary 14 Sona Nutrition Ltd: Competitive Position 2010

Adult Mouth Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • Although the continuing recession has discouraged some from expensive dental visits and to practice better dental hygiene, it has also had the effect of encouraging consumers to purchase products which are perceived to be better value for money. Many of these products tend not to fall into the adult mouth care category, such as mouthwashes, etc.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline leads Adult Mouth Care in 2010 with 31% value share with the Corsodyl brand. Reckitt Benckiser Plc’s Bonjela meanwhile further gained value share in 2010 growing to 16%.

PROSPECTS

  • Adult mouth care is expected to continue to experience steady growth over the forecast period, with a CAGR of 1% in constant value terms. Although the growth of popular oral care brands outside the category, such as Listerine, is expected to reduce the growth of this category, rising rates of self-medication will help to offset the sales lost to substitute products.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2005-2010
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 14 Adult Mouth Care Company Shares by Value 2006-2010
  • Table 15 Adult Mouth Care Brand Shares by Value 2007-2010
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in Ireland - Category Analysis

HEADLINES

TRENDS

  • August 2010 saw the introduction of strict new guidelines from the PSI (Pharmacy Society of Ireland), the pharmacy regulator, in relation to the suitability and sale of codeine-based analgesics in pharmacies due to concerns amongst the Irish healthcare community in relation to the highly addictive nature of codeine. All advertising of products, including window displays and leaflets, is now prohibited. Pharmacists are further advised to encourage the use of acetaminophen as the preferred first line of pain relief, followed by ibuprofen, before codeine-based analgesics should be used. Customers must now also be made aware of how to use the medication properly, as well as the possible side effects from use after the recommended period of three days, or from overdose.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline (Ireland) Ltd continued to lead analgesics with a 35% value share in 2010; Reckitt Benckiser Ireland Ltd remained in second place with a 28% value share. Wyeth Consumer Healthcare Ireland Ltd was ranked third with a 12% value share. Thus the leading three players alone accounted for a dominant 75% value share in 2010. Dominating their domestic counterparts due to economies of scale in marketing, these manufacturers each have strong portfolios of well-established brands. Irish consumers tend to be brand-loyal when it comes to analgesics, and on top of this are subjected to continuous television advertisements and pharmacist advice, which both exert significant influence.

PROSPECTS

  • Ireland has a low penetration of generic analgesics. This, however, is likely to change as consumers attempt to reduce costs wherever possible and concerned pharmacists further attempt to lower costs for their customers. The new agreement between the Department of Health and Children and The Association of Pharmaceutical Manufacturers of Ireland to cut the cost of off-patent prescription drugs by 40% should ensure that they will always be less expensive than their branded counterparts. Furthermore the Department of Health and Children is drafting legislation to introduce a system of reference pricing and generic substitution. This new agreement on prices for generic drugs will provide a pricing environment for the introduction of that system in 2011. This will encourage rising awareness of the effectiveness of generic products in the prescriptions category, which is also likely to influence the acceptance of these products across consumer health.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2005-2010
  • Table 19 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
  • Table 21 Analgesics Company Shares by Value 2006-2010
  • Table 22 Analgesics Brand Shares by Value 2007-2010
  • Table 23 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in Ireland - Category Analysis

HEADLINES

TRENDS

  • Increasingly hectic and stressful lifestyles, with more demands on time and longer working hours, are leaving an increasing number of Irish people feeling unable to relax and/or sleep. Many are turning to calming and sleeping products to help them relax and get a good night’s sleep. The growth rate was consistently high over the review period, as stress levels and the number of people suffering from insomnia continued to increase in Ireland.

SWITCHES

COMPETITIVE LANDSCAPE

  • Bach Flower Remedies Ltd continues to lead sales in Ireland with a value share of 25% in 2010. The Bach Rescue brand has benefited from the perception of ingredients being safe and natural, with counter-top displays in most chemists/pharmacies encouraging impulse buys. Bach Flower Remedies products are also considered by pregnant mothers to be safe for use during pregnancy, further supporting sales.

PROSPECTS

  • The calming and sleeping category in Ireland is expected to continue to perform well over the forecast period, as Irish consumers’ lives become more hectic and stressful. The category is expected to see a CAGR of 7% in constant value terms, to reach sales of €5.6 million by 2015.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2005-2010
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 27 Calming and Sleeping Company Shares by Value 2006-2010
  • Table 28 Calming and Sleeping Brand Shares by Value 2007-2010
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in Ireland - Category Analysis

HEADLINES

TRENDS

  • 2010 began as the coldest winter in living memory for most people in Ireland, as it was certainly the coldest since 1967, with night time temperatures repeatedly falling below -10°C during early January. With many roads impassable due to snow and ice, Ireland came to a virtual standstill for the better part of a fortnight. This, coupled with fears generated by the flu pandemic, which saw some consumers stocking up on cold and flu remedies, helped to maintain steady growth in the category. Additionally, the growing social trend to reduce sick leave, causing some to continue to work while self-medicating symptoms rather than take time off to recuperate, plus the higher incidence of allergies among the Irish population further aided the category to increase current value sales to €71 million in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Healthcare (Ireland) Ltd retained its leading position with a value share of 23%, while Reckitt Benckiser Ireland Ltd held a 22% share. Reckitt Benckiser’s success can be attributed to the strong position of its Strepsils and Lemsip brands, with the latter having long been a popular combination product. The brand has further extended its presence into the cough remedies category with the introduction of a variety of additions under the Lemsip Cough brand and as a result has continued to perform well. Having completed the takeover of Wyeth Consumer Healthcare, Pfizer Inc now has a value share of 2% in the category with the Robitussin and Advil brands

PROSPECTS

  • As economic conditions fail to improve, Ireland’s unemployment rate remains high at 13%, even as the numbers emigrating rise to levels not seen since the 1980s. Ireland has gone from having a shortage in the workforce to an over-supply of workers in a very few years. Employment levels are expected to fall by a further 1% in 2011 and remain stubbornly high over the forecast period. Those who remain in employment feel themselves coming under increasing pressure to maintain and improve performance and productivity. The result is an increase in the growing social trend to reduce the number of days taken as sick leave. This is contributing positively to the growth of the category, with many Irish consumers treating their cold and flu symptoms with a specific remedy; nearly one quarter of the population still treats such illnesses with analgesics alone. Consumers who make their purchases without the aid of a pharmacist’s recommendation will often select a well-known brand, given its well-established image, instead of a combination product, which might well be more effective in relieving a wider range of cold and flu symptoms.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 33 Sales of Decongestants by Category: Value 2005-2010
  • Table 34 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 35 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 36 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in Ireland - Category Analysis

HEADLINES

TRENDS

  • In April 2010, Swiss-owned company Nycomed Group launched its new proton pump inhibitor, Somac Control, to the Irish market having obtained approval to sell pantoprazole active ingredients over the counter throughout the EU in July 2009. Novartis Ireland Ltd also launched a similar product, Pantoloc Control, to the Irish OTC category. Both products contain 20mg of pantoprazole and are available in 7- or 14-unit blister packs. Proton pump inhibitors were well received in Ireland, achieving value sales of €2 million in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Healthcare (Ireland) Ltd maintained its leading position in digestive remedies in 2010, with a 28% value share, with Reckitt Benckiser Ireland Ltd and Bayer Ltd ranked second and third. Together the top four companies, which also include GlaxoSmithKline (Ireland) Ltd, accounted for 77% of total value sales in 2010. McNeil’s position was due to its Motilium, Pepcid, Imodium and Arret brands, while Gaviscon from Reckitt Benckiser continued to lead in brand terms with a 17% value share, followed by Bayer Ltd’s Rennie with 15%.

PROSPECTS

  • Modern hectic lifestyles and work schedules mean that Irish consumers increasingly require fast-acting and convenient products. Many purchasers are time-poor professionals; therefore discreet and easy-to-carry pills are generally preferable to cumbersome liquid formats. The success of Gaviscon’s Handy Pack, which retails for a considerably higher price per pill than the standard pack, demonstrates that demand for convenient packaging remains a key driver in the category. However consumers are striving to achieve value for money and this factor must not be overlooked as consumers seek products with lower price points and in this case lower price per pill, thus accounting for a 4% for the Rennie brand in 2010.

CATEGORY DATA

  • Table 41 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 42 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 43 Sales of Decongestants by Category: Value 2005-2010
  • Table 44 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 45 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 46 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 47 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 48 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 49 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 50 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Ear Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • Products within OTC ear care are used to treat two conditions: ear wax build-up and external canal infections (otitis externa), also known as “swimmers ear”. Ear wax build-up products can also be used as a preventative measure in patients prone to wax build-up.

SWITCHES

COMPETITIVE LANDSCAPE

  • SSL International Plc is the leading company within ear care in Ireland with a 32% value share, reflecting a further decline compared with all previous years in the review period. The company’s portfolio consists of two key brands in the category – Earex Ear Drops leads the category with a 22% value share while Audax is ranked fourth with 11%. Prior to 2008, the Audax brand was the second largest in the category; however, the Cerumol brand usurped its position in 2008 when it registered a share of 15%. However, due in part to the unpleasant aroma associated with Cerumol, the brand has begun to lose favour with consumers. Norgine Ltd’s Waxol is a popular recommendation amongst doctors and pharmacists and has grown in value share throughout the review period, from 3% in 2005 to 8% in 2010.

PROSPECTS

  • Value sales of ear care in Ireland are expected to remain effectively static over the forecast period in constant value terms. The category will remain stagnant unless new and more convenient products are introduced, as demonstrated by the success of Audispray from Diepharmex, which was launched in 2006 and which helped to reinvigorate sales.

CATEGORY DATA

  • Table 51 Sales of Ear Care: Value 2005-2010
  • Table 52 Sales of Ear Care: % Value Growth 2005-2010
  • Table 53 Ear Care Company Shares by Value 2006-2010
  • Table 54 Ear Care Brand Shares by Value 2007-2010
  • Table 55 Forecast Sales of Ear Care: Value 2010-2015
  • Table 56 Forecast Sales of Ear Care: % Value Growth 2010-2015

Eye Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • In the past Irish consumers have generally preferred to seek the advice of a doctor or eye specialist rather than self-medicate when suffering problems with the eyes. For this reason, prescription eye care is considerably more prevalent than OTC alternatives. The extended and severe recession has generated more thrift in Irish consumers, which has ensured a good level of growth within the eye care category as consumers convert to consulting with pharmacists before resorting to the more expensive option of doctors or specialists.

SWITCHES

COMPETITIVE LANDSCAPE

  • The emergence of private label products has had little impact on the eye care category to date. However, as consumers become more price conscious and more comfortable with non-branded and generic products this may change over the forecast period as the product range widens.

PROSPECTS

  • Eye care is expected to achieve a constant value CAGR of 1% over the forecast period. Its performance will be positively impacted by the more generalised use of products, however this will be restricted somewhat by reduced consumer spending on non-essential items in the early years of the forecast period. Allergy eye care, meanwhile, will continue to perform well due to the perceived necessity of use amongst many consumers.

CATEGORY DATA

  • Table 57 Sales of Eye Care by Category: Value 2005-2010
  • Table 58 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 59 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 60 Eye Care Company Shares by Value 2006-2010
  • Table 61 Eye Care Brand Shares by Value 2007-2010
  • Table 62 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 63 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in Ireland - Category Analysis

HEADLINES

TRENDS

  • Due to the recessionary conditions in Ireland, the key to sales is value for money. Cash-strapped Irish consumers continue to seek out better value for money wherever possible. With the cost of many herbal/traditional products at a premium compared with their standard counterparts, many Irish consumers have had a rethink in relation to these items. However, the Irish consumers’ continuing interest in natural products continues to encourage growth in the category, especially in relation to topical treatments such as herbal/traditional medicated skincare, which saw growth of 4% in 2010.

COMPETITIVE LANDSCAPE

  • Herbal/traditional products was dominated by Cadbury Ireland Ltd with 16% of total value sales in 2010. The competitive environment within herbal/traditional products in 2010 remained fragmented due to the wide range and scope of the products which fall under this classification. However, the prominent players included Lane Health Products Ltd, GR with 6% value sales, Seven Seas Ireland Ltd, Chefaro Ireland Ltd and Sons Nutrition Ltd each accounting for 5% value sales.

PROSPECTS

  • The effective regulation of herbal/traditional products through the implementation of the the Medicinal Products (Prescription and Control of Supply) Regulations 2007 which came into effect on 23 July 2007 requires that no medicinal product can be placed on the market without being registered via a marketing authorisation or certificate of traditional-use registration. The regulations provided an exemption from this requirement until 30 April 2011 for herbal/traditional products on the market in Ireland prior to July 2007. This restriction will hinder new product developments over the forecast period due to the time and cost involved in registering new products. Furthermore, growth in the category may contract further in 2011, as any product that has not been registered by this time will be taken off the shelves.

CATEGORY DATA

  • Table 64 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 65 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 66 Herbal/Traditional Products Company Shares 2006-2010
  • Table 67 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 68 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 69 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • The medicated skin care category is mature, and saw a fall in growth rates similar to that seen in the preceding years as many Irish consumers continue to tighten their belts. Acne treatments saw a small increase in value sales of 0.5% reaching €8 million as consumers continue to resort to OTC products rather than incur expensive doctor and prescription fees.

SWITCHES

COMPETITIVE LANDSCAPE

  • McNeil Healthcare (Ireland) Ltd led medicated skin care in 2010 with a 22% share of value sales. McNeil Healthcare boasted the leading position in hair loss treatments, medicated shampoos and haemorrhoid treatments, as well as the second position in topical antifungals, vaginal antifungals, antipruritics and acne treatments.

PROSPECTS

  • The protracted recession has reduced the amount of disposable income available to many Irish consumers, leading them to seek out savings wherever possible. Increased interest in private label and generic products is one result of this process. Although generic products are not particularly prevalent in the medicated skincare category, restricted to specific areas, it is likely that the increased availability of products and sustained consumer interest will steadily increase performance over the forecast period. In the current circumstances, consumers are more than willing to “trade down” to less expensive products, a shift which may affect the value performance of the category.

CATEGORY DATA

  • Table 70 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 71 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 72 Acne Treatments by Format: % Value Breakdown 2005-2010
  • Table 73 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 74 Medicated Skin Care Brand Shares by Value 2007-2010
  • Table 75 Acne Treatments Brand Shares by Value 2007-2010
  • Table 76 Hair Loss Treatments Brand Shares by Value 2007-2010
  • Table 77 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 78 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in Ireland - Category Analysis

HEADLINES

TRENDS

  • The results of the Office of Tobacco Control’s research on current trends in tobacco smoking indicate that in 2010 the overall smoking prevalence has declined to 23.6%, with rates for both men and women declining steadily over the past two years. Meanwhile ASH Ireland has repeated its appeal for a reduction in the price of and access to NRT smoking cessation aids which continue to be restricted to chemists/pharmacies and parapharmacies/drugstores, placing an obstacle to growth. The IHF (Irish Heart Foundation) also called on the government to help smokers to quit using significant increases in tobacco tax, anti-smuggling measures and smoking cessation programmes.

SWITCHES

COMPETITIVE LANDSCAPE

  • Nicorette from McNeil Healthcare (Ireland) Ltd leads NRT smoking cessation aids in 2010, with a 68% share of value sales. The brand’s continued success in NRT gum remains partially offset by losses in the second-largest category, NRT patches. Many consumers have a preference for the Niquitin CQ Clear Patch from GlaxoSmithKline (Ireland) Ltd and this alongside a strong television advertising campaign encouraged strong growth in 2010 within the NRT patches category.

PROSPECTS

  • The Irish government and the EU are keen to reduce smoking by making life more problematic for smokers, thereby encouraging them to quit through the implementation of tighter regulations and price increases on tobacco. The EU ruling in relation to minimum price bans could pave the way for below cost selling of cigarettes by manufacturers and provide an opportunity for increased tax revenues through higher excise duties on cigarettes. However, the taxes on cigarettes in December 2010 budget remained unchanged with the government citing the law of diminishing returns and concerns in relation to potential increases in smuggling and subsequent impact on exchequer returns. Ireland is already the most expensive place to purchase cigarettes in the EU. Either way, continuing economic uncertainty and budget severity is likely to encourage more smokers to quit in the coming years.

CATEGORY INDICATORS

  • Table 79 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 80 Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
  • Table 81 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
  • Table 82 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 83 NRT Smoking Cessation Aids Company Shares by Value 2006-2010
  • Table 84 NRT Smoking Cessation Aids Brand Shares by Value 2007-2010
  • Table 85 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

Sports Nutrition in Ireland - Category Analysis

HEADLINES

TRENDS

  • Although sports nutrition continued to grow in 2010, it was at a slower rate than that seen in previous years due to Ireland’s poor economic conditions. Gym memberships have fallen by approximately 15-20% over 2009 and 2010, further reducing the exposure of many products to consumers. This may go some way to explain the appearance of some products in the supermarkets channel. Additionally, sports nutrition is now part of a very profitable health and fitness industry in Ireland, supported by increasing awareness of the benefits of a healthy lifestyle.

COMPETITIVE LANDSCAPE

  • Maxinutrition Ltd remained the leading company within sports nutrition in Ireland with a 14% retail value share in 2010, with brands such as Maximuscle, Cyclone, Promax, Progain and Promax Extreme and the expansion of female-orientated brands Sculptress, Definity and Finesse. Unlike other companies, Maximuscle products are widely available through major healthfood shops around Ireland, as well as in gyms and through the internet retailing channel. This gives the company a significant advantage over other manufacturers in terms of strong and varied distribution. However, the company’s share has declined from its 2007 level because of an increased product selection resulting from several new distribution websites in Ireland.

PROSPECTS

  • Continuing economic worries and reduced spending capacity indicate that the growth rate over the forecast period is expected to be considerably slower than that of the review period. By 2015, the category is expected to reach sales of €7.4 million with a constant value CAGR of 1% over the forecast period. Additionally, competition in terms of online distribution is likely to become more pronounced as a result of greater access to reliable broadband services and increased acceptance of the format.

CATEGORY DATA

  • Table 87 Sales of Sports Nutrition: Value 2005-2010
  • Table 88 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 89 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 90 Sports Nutrition Company Shares 2006-2010
  • Table 91 Sports Nutrition Brand Shares 2007-2010
  • Table 92 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 93 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015
  • Table 94 Sports Nutrition, category rankings 2010

Vitamins and Dietary Supplements in Ireland - Category Analysis

HEADLINES

TRENDS

  • Due to the recessionary conditions in Ireland, the key to sales is value for money. Cash-strapped Irish consumers continue to seek better value for money wherever possible. This has led to the continued increase in sales of multivitamin and multi-benefit combination products. The growing trend towards health maintenance and illness prevention has further increased sales as more consumers become better informed of the benefits of the various vitamins and dietary supplements available to them.

Vitamins

Dietary Supplements

COMPETITIVE LANDSCAPE

  • Seven Seas Ireland Ltd continues to hold the top position in vitamins and dietary supplements in Ireland for 2010, with a 28% value share in the category. The company has a long-established, exceptionally strong brand which is immediately recognisable amongst consumers. This is in part due to its presence in Ireland for more than 20 years and also to aggressive new product development and extensive marketing support all year round. Seven Seas Ireland held the leading position in fish oils and mineral supplements, with 55% and 42% of value sales respectively in 2010, achieved largely through strong sales of its Haliborange and Seven Seas Cod Liver Oil ranges. It also held the leading share of child-specific vitamins and dietary supplements. Furthermore, with its expansive portfolio of products, the company also led the following categories in terms of value sales: combination dietary supplements, single vitamins, garlic, ginseng, evening primrose oil and tonics and bottled nutritive drinks.

PROSPECTS

  • Self-medication and health and wellness have become key components of Irish consumer lifestyles. Vitamins and dietary supplements, once viewed as a means of recuperation after illness or when “in need of a tonic”, are now accepted as being beneficial to health on an ongoing basis. This trend is expected to continue to strengthen over the forecast period, helping to maintain growth in the vitamins and dietary supplements category through increased penetration and higher frequency of use. However, continuing poor economic conditions will put pressure on disposable incomes, making consumers more mindful of their expenditure. As a result continued promotional activity can be expected with minimal price increases which may ultimately lead to slower growth. Over the forecast period, the constant value CAGR is expected to be slower than the review period at 1%.

CATEGORY DATA

  • Table 95 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 96 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 97 Dietary Supplements by Positioning 2005-2010
  • Table 98 Vitamins and Dietary Supplements Company Shares by Value 2006-2010
  • Table 99 Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
  • Table 100 Vitamins Brand Shares by Value 2007-2010
  • Table 101 Dietary Supplements Brand Shares by Value 2007-2010
  • Table 102 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 103 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015
  • Summary 15 Summary Dietary Supplements Brand Ranking by Positioning

Weight Management in Ireland - Category Analysis

HEADLINES

TRENDS

  • Since its launch in April 2009 Alli has been a runaway success, achieving sales well above expectations, despite some bad press received in the US, where GlaxoSmithKline saw sales fall by 18% in the last quarter of 2009 in relation to possible side effects affecting liver function. Sales have been well supported in Ireland with a high-profile television advertising campaign and copious online support from the dedicated Alli website.

COMPETITIVE LANDSCAPE

  • Allegro Holdings Ltd with the Slim Fast range of products and GlaxoSmithKline (Ireland) Ltd dominate the weight management category, each with value shares over 20%. Slim Fast is a well-established brand in Ireland with a proven record and a wide range of products, while Alli is attractive to many due to the simplicity of the format – one pill three times a day – which suits the hectic lifestyle of many Irish consumers.

PROSPECTS

  • Ireland has an ongoing love affair with weight loss and the industry that surrounds it. The economic downturn can be expected to stifle growth to some extent, however with highly visible media and celebrity pressure, government campaigns around obesity prevention and the growing lifestyle trend towards health and wellness it is likely that the category will continue to grow over the forecast period, achieving a constant value CAGR of 3% to 2015.

CATEGORY DATA

  • Table 104 Sales of Weight Management: Value 2005-2010
  • Table 105 Sales of Weight Management: % Value Growth 2005-2010
  • Table 106 Weight Management Company Shares 2006-2010
  • Table 107 Weight Management Brand Shares 2007-2010
  • Table 108 Forecast Sales of Weight Management: Value 2010-2015
  • Table 109 Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in Ireland - Category Analysis

HEADLINES

TRENDS

  • Products within the first aid kits category are not sold in large volumes in Ireland. They are mainly sold in the chemists/pharmacies and parapharmacies/drugstores channels, with smaller handy kits performing slightly better in the supermarkets channel, due to better price promotions.

COMPETITIVE LANDSCAPE

  • Beiersdorf Ireland Ltd’s Elastoplast remains the leading brand in wound care with a 33% value share in 2010, down from 34% in 2009 and 35% in 2008 as consumers continue to switch to less expensive brands. Fleming Medical Ltd, the leading company in First Aid Kits, saw a drop in share in 2010 due to increased availability and uptake of smaller, more convenient mini first aid kits.

PROSPECTS

  • The wound care category in Ireland is mature and only expected see a marginal decline over the forecast period. While an easing of recessionary conditions and the associated improvement in disposable incomes may encourage spending on premium products, especially in relation to those aimed at younger children, the majority of consumers will continue to purchase the same types of products that they always have.

CATEGORY DATA

  • Table 110 Sales of Wound Care by Category: Value 2005-2010
  • Table 111 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 112 Wound Care Company Shares by Value 2006-2010
  • Table 113 Wound Care Brand Shares by Value 2007-2010
  • Table 114 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 115 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Artichoke
            • Green Tea Extract
            • Isoflavones
            • Starflower Oil
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
        • Tonics and Bottled Nutritive Drinks
        • Vitamins
          • Multivitamins
          • Single Vitamins
            • Vitamin A
            • Vitamin B
            • Vitamin C
            • Vitamin D
            • Vitamin E
            • Other Single Vitamins
      • Weight Management
        • Meal Replacement Slimming
        • OTC Obesity
        • Slimming Teas
        • Weight Loss Supplements
        • Other Slimming Products
      • Herbal/Traditional Products
        • Herbal/Traditional Analgesics
        • Herbal/Traditional Calming and Sleeping Products
        • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
        • Herbal/Traditional Digestive Remedies
        • Herbal/Traditional Medicated Skin Care
        • Herbal/Traditional Medicinal Teas
        • Herbal/Traditional Smoking Cessation Aids
        • Herbal/Traditional Child-Specific Dietary Supplements
        • Herbal/Traditional Dietary Supplements
        • Herbal/Traditional Tonics and Bottled Nutritive Drinks
      • Allergy Care
        • Allergy Eye Care
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Allergy Remedies
        • Topical Allergy Remedies/Antihistamines
      • Child-Specific Consumer Health
        • Child-Specific Analgesics
          • Child-Specific Acetaminophen
          • Child-Specific Aspirin
          • Child-Specific Combination Products - Analgesics
          • Child-Specific Diclofenac
          • Child-Specific Dipyrone
          • Child-Specific Ibuprofen
          • Child-Specific Ketoprofen
          • Child-Specific Naproxen
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Child-Specific Medicated Skin Care
        • Nappy (Diaper) Rash Treatments
        • Child-Specific Vitamins and Dietary Supplements

    Statistics Included

    Statistics Included

    For each category and subcategory you will receive the following data in Excel format:

    From Passport

    • Market sizes
    • Company shares
    • Brand shares
    • Distribution
    • Analysis by format
    • Analysis by positioning
    • Analysis by type
    • Herbal/traditional vs standard
    • Pricing

    Market size details:

    • Retail volume
    • Retail volume % growth
    • Retail volume per capita
    • Retail value retail selling price % growth
    • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price real (constant 2008) prices % growth
    • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price % growth
    • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price real (constant 2008) prices % growth
    • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price nominal (current) prices % growth
    • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price nominal (current) prices % growth
    • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

    Methodology

    Methodology

    Global insight and local knowledge

    With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

    This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

    Industry specialists

    Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

    Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

    The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

    Country and regional analysts

    Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

    In-country research network

    To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

    Research Methodology

    Our research methods

    Each Euromonitor International industry report is based on a core set of research techniques:

    Desk research

    With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

    • National statistics offices governmental and official sources
    • National and international trade press
    • National and international trade associations
    • Industry study groups and other semi-official sources
    • Company financials and annual reports
    • Broker reports
    • Online databases
    • The financial, business and mainstream press

    Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

    Store checks

    Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

    • Place: We track products in all relevant channels, selective and mass, store and non-store
    • Product: What are innovations in products, pack sizes and formats?
    • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
    • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

    Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

    Trade survey

    Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

    Trade surveys allow us to:

    • Fill gaps in available published data per company
    • Generate a consensus view of the size, structure and strategic direction of the category
    • Access year-in-progress data where published sources are out of date
    • Evaluate the experts’ views on current trends and market developments

    In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

    Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

    Company analysis

    At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

    At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

    Forecasts

    Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

    Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

    Data validation

    All data is subjected to an exhaustive review process, at country, regional and global levels.

    The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

    Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

    Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

    Market analysis

    Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

    Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

    my pages

    Want to find out more about this report?

    If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!

    RELATED

    Country Report

    Consumer Lifestyle

    Future Demographic

    Country Report